Alaunos terminates SVP Legal and VP R&D; execs receive separation payments, consulting

Alaunos Therapeutics, Inc.

Melinda Lackey (SVP, Legal) and Drew Deniger (VP, R&D) terminated without cause, effective Nov 15, 2023.
Lackey receives $180,000 separation payment; Deniger receives $182,500 separation payment.
Lackey enters consulting agreement at $400/hour to assist with strategic alternatives review.
Deniger agrees to cooperate on investigations and strategic alternatives for scientific assets.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Melinda Lackey

Senior Vice President, Legal and Administration

TCRT · Alaunos Therapeutics, Inc.

Effective: 2023-11-15
Filed: November 15, 2023, 6:59 PM ET

the Company terminated the employment of Melinda Lackey, Senior Vice President, Legal and Administration

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Melinda Lackey was terminated as Senior Vice President, Legal and Administration at Alaunos Therapeutics, Inc..

Action: terminated
Role: Senior Vice President, Legal and Administration

Exact text from the filing

the Company terminated the employment of Melinda Lackey, Senior Vice President, Legal and Administration

View on SEC.gov

Alaunos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-277541

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.